Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Kabi, is a 5-HT3 receptor antagonist presented as an intravenous solution for IV use. It is used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adult and pediatric patients. GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways. - Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting: decreases incidence of nausea and vomiting after surgery.

Common Side Effects: - Headache - Constipation - Fatigue - Dizziness - Injection site pain - Diarrhea

Serious or Rare Side Effects: - QT interval prolongation - Severe allergic reaction (anaphylaxis) - Serotonin syndrome - Cardiac arrhythmias - Hepatic dysfunction - Severe hypotension

When using Ondansetron Kabi, clinicians should consider the following precautions: - Cardiac monitoring: assess risk for QT prolongation, especially in patients with cardiac disease. - Electrolyte balance: ensure electrolytes are stable to reduce risk of arrhythmia during treatment. - Concomitant serotonergic drugs: review the patient for potential interactions that may increase serotonin levels and risk of serotonin syndrome. - Pregnancy and breast‑   ---   - Renal  - Store at 2-8°C: keep refrigerated and protect from light and freeze as the product must remain stable for its intended the   -  

The    

---